{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-026868","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.515584+00:00","generated_at":"2026-06-05T02:49:00.474416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TScan Q4 net loss $19.6M; all 8 TSC-100/101 patients relapse-free","bullets":["Q4 revenue $7.2M (up from $3.1M YoY); full-year revenue $21.0M. R&D expenses $22.4M Q4, $88.2M full year.","Cash $192M as of Dec 31, 2023; cash runway into 2026.","Phase 1 heme data: 8/8 treatment-arm patients relapse-free; one high-risk MDS patient reached 1 year post-TSC-101.","FDA cleared INDs for TSC-201-B0702 (MAGE-C2) and TSC-204-A0101 (MAGE-A1); solid tumor trial enrolling.","Appointed Jason Amello as CFO, Justin McCue as CTO; promoted several executives."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-026868","json":"https://secwatch.observer/filing/0000950170-24-026868.json","markdown":"https://secwatch.observer/filing/0000950170-24-026868.md","text":"https://secwatch.observer/filing/0000950170-24-026868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/0000950170-24-026868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/tcrx-20240306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:49:00.474416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9ef44dfbbfe4f4966ce4fb50eda610aa2c02b89","claim":"TScan Therapeutics, Inc. reported financial results for the three months and full year ended December 31, 2023.","evidence_excerpt":"TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017024026868/0000950170-24-026868-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}